Malaria remains a global health challenge, and in recent days, several developments have emerged in both the fight against the disease and the ongoing rollout of vaccines. On August 8, it was reported by The World that Ghana has approved the world's first malaria drug specifically for newborns. The medication, called Coartem Baby, is the result of nearly a decade of research and dissolves in breast milk, making it both safe and effective for infants. This marks a major advance in infant malaria care, yet concerns remain as US funding cuts have put crucial malaria research in Africa at risk, leaving experts in Ghana alarmed over a $10 million gap in their malaria elimination budget.
In Uganda, the fight against malaria intensified earlier this year. Seed Global Health highlighted ongoing efforts since April 2025 to integrate the malaria vaccine into child immunization schedules across 105 districts identified with high or moderate transmission. Uganda ranks third in malaria burden among African nations—according to the latest WHO report—and the inclusion of the vaccine is expected to make a significant impact on child mortality and public health. The country’s campaign emphasizes not only delivering the vaccine but also training health workers to build trust within communities and educate caregivers.
Elsewhere on the continent, Rwanda is reconsidering the use of malaria vaccines after a surprise surge in cases following years of progress, as Malaria World reported on August 6. This renewed evaluation includes vaccines that the country had previously declined, showing a growing willingness to adopt new preventive measures as the situation evolves.
Globally, vaccine research continues to push boundaries. On August 7, Malaria World published findings of a new bivalent viral vectored malaria vaccine—the m8Δ vaccine—which offers protection against both Plasmodium falciparum and Plasmodium vivax, effectively targeting two of the most dangerous malaria parasites. This advance is joined by another significant stride announced by WEHI, where researchers used cryo-electron microscopy to reveal a previously unknown region in the malaria parasite’s fertilization complex. Their work identified new domains on proteins Pfs230 and Pfs48/45 as potent vaccine targets, opening the possibility of blocking the parasite’s transmission by up to 99.7 percent.
Commercial deployment of vaccines is also expanding. Novavax, in partnership with Serum Institute of India and Oxford University, announced that its R21/Matrix-M malaria vaccine has sold 20 million doses since its mid-2024 launch, according to the company’s second quarter results released on August 6. The vaccine is addressing urgent needs in malaria-endemic regions, but distribution remains largely concentrated in high-transmission areas, primarily in Africa.
In the United States, malaria remains rare and travel-related, but new developments have arisen. News outlets including the Spokesman-Review and Vax-Before-Travel report a possible first instance of locally transmitted malaria in Washington State—a woman in Pierce County who has not traveled recently was diagnosed earlier this month. If confirmed, this would be the first known case west of the Rockies, and health officials are investigating and testing local mosquitoes. Generally, 2,000 to 2,500 malaria cases are reported annually in the U.S., almost always tied to travel from countries where malaria transmission is active. While Africa has two malaria vaccines available, as of August 7, 2025, these vaccines are not yet available in the United States.
This week’s updates underscore both scientific progress and persistent global obstacles in the malaria fight. The rapid advancement of new vaccines and treatments raises hope, but logistical hurdles, funding challenges, and unequal vaccine access continue to complicate the path towards global malaria elimination.
This content was created in partnership and with the help of Artificial Intelligence AI
In Uganda, the fight against malaria intensified earlier this year. Seed Global Health highlighted ongoing efforts since April 2025 to integrate the malaria vaccine into child immunization schedules across 105 districts identified with high or moderate transmission. Uganda ranks third in malaria burden among African nations—according to the latest WHO report—and the inclusion of the vaccine is expected to make a significant impact on child mortality and public health. The country’s campaign emphasizes not only delivering the vaccine but also training health workers to build trust within communities and educate caregivers.
Elsewhere on the continent, Rwanda is reconsidering the use of malaria vaccines after a surprise surge in cases following years of progress, as Malaria World reported on August 6. This renewed evaluation includes vaccines that the country had previously declined, showing a growing willingness to adopt new preventive measures as the situation evolves.
Globally, vaccine research continues to push boundaries. On August 7, Malaria World published findings of a new bivalent viral vectored malaria vaccine—the m8Δ vaccine—which offers protection against both Plasmodium falciparum and Plasmodium vivax, effectively targeting two of the most dangerous malaria parasites. This advance is joined by another significant stride announced by WEHI, where researchers used cryo-electron microscopy to reveal a previously unknown region in the malaria parasite’s fertilization complex. Their work identified new domains on proteins Pfs230 and Pfs48/45 as potent vaccine targets, opening the possibility of blocking the parasite’s transmission by up to 99.7 percent.
Commercial deployment of vaccines is also expanding. Novavax, in partnership with Serum Institute of India and Oxford University, announced that its R21/Matrix-M malaria vaccine has sold 20 million doses since its mid-2024 launch, according to the company’s second quarter results released on August 6. The vaccine is addressing urgent needs in malaria-endemic regions, but distribution remains largely concentrated in high-transmission areas, primarily in Africa.
In the United States, malaria remains rare and travel-related, but new developments have arisen. News outlets including the Spokesman-Review and Vax-Before-Travel report a possible first instance of locally transmitted malaria in Washington State—a woman in Pierce County who has not traveled recently was diagnosed earlier this month. If confirmed, this would be the first known case west of the Rockies, and health officials are investigating and testing local mosquitoes. Generally, 2,000 to 2,500 malaria cases are reported annually in the U.S., almost always tied to travel from countries where malaria transmission is active. While Africa has two malaria vaccines available, as of August 7, 2025, these vaccines are not yet available in the United States.
This week’s updates underscore both scientific progress and persistent global obstacles in the malaria fight. The rapid advancement of new vaccines and treatments raises hope, but logistical hurdles, funding challenges, and unequal vaccine access continue to complicate the path towards global malaria elimination.
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Malaria remains a global health challenge, and in recent days,
several developments have emerged in both the fight against the
disease and the ongoing rollout of vaccines. On August eighth,
it was reported by the World that Ghana has approved
the world's first malaria drug specifically for newborns. The medication,
(00:20):
called cortum Baby, is the result of nearly a decade
of research and dissolves in breast milk, making it both
safe and effective for infants. This marks a major advance
in infant malaria care, yet concerns remain as US funding
cuts have put crucial malaria research in Africa at risk,
leaving experts in Ghana alarmed over a ten million dollar
(00:40):
gap in their malaria elimination budget. In Uganda, the fight
against malaria intensified earlier this year. SEED Global Health highlighted
ongoing efforts since Ape twenty twenty five to integrate the
malaria vaccine into child immunization schedules across one hundred and
five districts identified with high moderate transmission. Uganda ranks third
(01:03):
in malaria burden among African nations according to the latest
WHO report, and the inclusion of the vaccine is expected
to make a significant impact on child mortality and public health.
The country's campaign emphasizes not only delivering the vaccine, but
also training health workers to build trust within communities and
educate caregivers elsewhere on the continent. Rwanda is reconsidering the
(01:28):
use of malaria vaccines after a surprise surge in cases
following years of progress. As Malaria World reported on August six,
this renewed evaluation includes vaccines that the country had previously declined,
showing a growing willingness to adopt new preventive measures as
the situation evolves. Globally, vaccine research continues to push boundaries.
(01:51):
On August seventh, Malaria World published findings of a new
bivalent viral vectored malaria vaccine, them a della vaccine, which
offers protection against both Plasmodium falciparum and Plasmodium vivas, effectively
targeting two of the most dangerous malaria parasites. This advance
is joined by another significant stride announced by WIHI, where
(02:12):
researchers used cryoelectron microscopy to reveal a previously unknown region
in the malaria parasite's fertilization complex. Their work identified new
domains on penes PFS two thirty and PFS forty eight
forty five as potent vaccine targets, opening the possibility of
blocking the parasite's transmission by up to ninety nine point
(02:32):
seven percent. Commercial deployment of vaccines is also expanding. Novavax,
in partnership with Serum Institute of India and Oxford University,
announced that its R twenty one Matrix and malaria vaccine
has sold twenty million doses since its mid twenty twenty
four launch, according to the company's second quarter results released
on August six. The vaccine is addressing urgent needs in
(02:56):
malaria endemic regions, but distribution remains largely concentrate in high
transmission areas, primarily in Africa. In the United States, malaria
remains rare and travel related, but new developments have arisen.
News outlets including The Spokesman Review and VAS Before Travel
report a possible first instance of locally transmitted malaria in
(03:18):
Washington State. A woman in Pierce County who has not
traveled recently, was diagnosed earlier this month. If confirmed, this
would be the first known case west of the Rockies,
and health officials are investigating and testing local mosquitoes. Generally,
two thousand to twenty five hundred malaria cases are reported
(03:38):
annually in the U S, almost always tied to travel
from countries where malaria transmission is active. While Africa has
two malaria vaccines available as of August seven, twenty twenty five,
these vaccines are not yet available in the United States.
This week's updates underscore both scientific progress and persistent global
(03:59):
obstacles in the malaria fight. The rapid advancement of new
vaccines and treatments raises hope, but logistical hurdles, funding challenges,
and unequal vaccine access continue to complicate the path towards
global malaria elimination.
Malaria remains a global health challenge, and in recent days,
several developments have emerged in both the fight against the
disease and the ongoing rollout of vaccines. On August eighth,
it was reported by the World that Ghana has approved
the world's first malaria drug specifically for newborns. The medication,
(00:20):
called cortum Baby, is the result of nearly a decade
of research and dissolves in breast milk, making it both
safe and effective for infants. This marks a major advance
in infant malaria care, yet concerns remain as US funding
cuts have put crucial malaria research in Africa at risk,
leaving experts in Ghana alarmed over a ten million dollar
(00:40):
gap in their malaria elimination budget. In Uganda, the fight
against malaria intensified earlier this year. SEED Global Health highlighted
ongoing efforts since Ape twenty twenty five to integrate the
malaria vaccine into child immunization schedules across one hundred and
five districts identified with high moderate transmission. Uganda ranks third
(01:03):
in malaria burden among African nations according to the latest
WHO report, and the inclusion of the vaccine is expected
to make a significant impact on child mortality and public health.
The country's campaign emphasizes not only delivering the vaccine, but
also training health workers to build trust within communities and
educate caregivers elsewhere on the continent. Rwanda is reconsidering the
(01:28):
use of malaria vaccines after a surprise surge in cases
following years of progress. As Malaria World reported on August six,
this renewed evaluation includes vaccines that the country had previously declined,
showing a growing willingness to adopt new preventive measures as
the situation evolves. Globally, vaccine research continues to push boundaries.
(01:51):
On August seventh, Malaria World published findings of a new
bivalent viral vectored malaria vaccine, them a della vaccine, which
offers protection against both Plasmodium falciparum and Plasmodium vivas, effectively
targeting two of the most dangerous malaria parasites. This advance
is joined by another significant stride announced by WIHI, where
(02:12):
researchers used cryoelectron microscopy to reveal a previously unknown region
in the malaria parasite's fertilization complex. Their work identified new
domains on penes PFS two thirty and PFS forty eight
forty five as potent vaccine targets, opening the possibility of
blocking the parasite's transmission by up to ninety nine point
(02:32):
seven percent. Commercial deployment of vaccines is also expanding. Novavax,
in partnership with Serum Institute of India and Oxford University,
announced that its R twenty one Matrix and malaria vaccine
has sold twenty million doses since its mid twenty twenty
four launch, according to the company's second quarter results released
on August six. The vaccine is addressing urgent needs in
(02:56):
malaria endemic regions, but distribution remains largely concentrate in high
transmission areas, primarily in Africa. In the United States, malaria
remains rare and travel related, but new developments have arisen.
News outlets including The Spokesman Review and VAS Before Travel
report a possible first instance of locally transmitted malaria in
(03:18):
Washington State. A woman in Pierce County who has not
traveled recently, was diagnosed earlier this month. If confirmed, this
would be the first known case west of the Rockies,
and health officials are investigating and testing local mosquitoes. Generally,
two thousand to twenty five hundred malaria cases are reported
(03:38):
annually in the U S, almost always tied to travel
from countries where malaria transmission is active. While Africa has
two malaria vaccines available as of August seven, twenty twenty five,
these vaccines are not yet available in the United States.
This week's updates underscore both scientific progress and persistent global
(03:59):
obstacles in the malaria fight. The rapid advancement of new
vaccines and treatments raises hope, but logistical hurdles, funding challenges,
and unequal vaccine access continue to complicate the path towards
global malaria elimination.
Popular Podcasts
On Purpose with Jay Shetty
I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.